Wednesday 29th July 2020
|Text too small?|
AFT Pharmaceuticals (NZX: AFT , ASX:AFT) today welcomes Medsafe’s announcement that all codeine and codeine-containing medicines will become prescription only from 5 November 2020.
Medsafe, which made the decision to reschedule all codeine and codeine-containing medicines last year, announced the timetable to give effect to the decision in a letter to the pharmaceutical industry released earlier this week.
The letter is attached to this release.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are pleased Medsafe has set a firm date for the rescheduling of codeine. We expect the move, which is aimed at reducing codeine overdoses and poisonings, will increase demand for alternative pain relief treatments including, AFT’s patented paracetamol and ibuprofen combination treatment Maxigesic.”
“In the 12 months after Australia rescheduled codeine containing medicines in 2018, sales of Maxigesic tablets increased by more than 50%. While it is unclear whether the New Zealand market will respond in a similar way, we expect the move to assist the growth of Maxigesic in New Zealand in the current financial year.”
Source: AFT Pharmaceuticals (NZX: AFT , ASX:AFT)
No comments yet
Reserve Bank of New Zealand Committed to Action as It Responds to Data Breach
MHM Automation Limited (NZX: MHM) Settlement of New Plymouth Building Sale
Napier Port Holdings Limited (NZX: NPH) First Quarter 2021 Trade Volumes
New Zealand Oil & Gas Limited (NZX: NZO) Mahato PSC Update - Oil Production
Michael Hill International Limited (NZX: MHJ) Update - Dividend/Distribution
Michael Hill International Limited (NZX: MHJ) Trading Update
Tilt Renewables Limited (NZX: TLT) Q3 December 2020 Quarterly Production Results
Mercury NZ Limited (NZX: MCY) Tiwai to continue operations through 2024
NZXO Announcement: Rollover of Fletcher Building Industries Ltd Notes - FBI150
Meridian Energy Limited (NZX: MEL) Rio Tinto confirms Tiwai Exit in December 2024